The OBIO® 2027 Early Technology Showcase (ETS) will feature presentations from Canada’s leading research institutions and healthcare organizations to global investors. ETS partners are invited to present the most promising technologies as well as introduce projects with the greatest potential for commercialization in their research portfolios and emerging health science companies.
Presenting organizations
The McGill Dobson Centre for Entrepreneurship is McGill University’s hub for innovation and venture creation. We support a global community of 690+ startups that hold 624 active patents, raised $4.6B, and created 13,000 jobs across 35 countries.
With over a third of our portfolio in life sciences, and McGill’s ranking among the best universities for medical research, we are proud to support some of the most cutting-edge discoveries in biotechnology, precision medicine, and medical devices as they commercialize nationally and internationally.
Recognized globally for our ecosystem, we are proud to count partnerships with Mass General Brigham, Harvard Innovation, and the London Institute for Healthcare Engineering at King’s College London.
As an expert navigator of the Canadian health care, regulatory, and technology landscape, PHC Ventures provides indispensable support to corporate, institutional and individual innovators seeking to validate and commercialize their products and ideas. PHC Ventures offers a portal to Providence Health Care in Vancouver, Canada, a renowned provincial health organization whose lengthy innovation track record and size make it an ideal incubator to validate and scale innovations. PHC Ventures actively co-develops health solutions, validate and test healthcare solutions in clinics, facilitates consulting relationships with PHC clinicians, invests in health start-ups, and leverages medical data for AI development and complex research projects.
The Stem Cell Network (SCN) is a mission-driven not-for-profit organization that unites researchers, clinicians, industry leaders, and health champions dedicated to transforming lives through regenerative medicine. As Canada’s only national organization with a specific focus on this field, SCN is uniquely positioned to drive progress in the fight against disease and power Canada’s economy through company creation and the development of future leaders.
For nearly 25 years, SCN has built a trusted, collaborative network that aligns researchers, clinicians and bioentrepreneurs across Canada and globally. Through a small but dedicated staff team and the support of expert volunteers, SCN effectively delivers research programs, mentors emerging talent, accelerates the development of cutting-edge therapies, and supports the growth of biotech companies across Canada.
Since its inception, SCN has invested over $162 million in Canadian regenerative medicine research, leveraging an additional $176 million from partners. This funding has positioned Canada as a global leader in regenerative medicine, fostering world-class expertise, spinning out innovative biotech companies, and pioneering life-changing clinical trials.